Literature DB >> 8269593

Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.

B C Baguley1, G Cole, L L Thomsen, Z Li.   

Abstract

The relationship of serotonin (5-HT) receptors to the action of the experimental antitumour drugs flavone-8-acetic acid (FAA) and 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA) was studied. Both FAA and 5,6-MeXAA are known to induce the synthesis of tumour necrosis factor-alpha (TNF) and to stimulate nitric oxide synthesis in vivo, as measured by elevation of plasma nitrate. Serotonin potentiated the effect of a subtherapeutic dose of 5,6-MeXAA (20 mg/kg) as measured both by plasma nitrate increase and by growth delay of s.c. implanted colon 38 tumours. On the other hand, administration of the serotonin 5-hydroxytryptamine-2 (5-HT2) antagonist cyproheptadine (20 mg/kg) inhibited both the plasma nitrate response and, to a lesser extent, the induction of tumour haemorrhagic necrosis by 5,6-MeXAA, FAA and TNF. Reduction of circulating plasma serotonin by pre-treatment with p-chlorophenylalanine and reserpine reduced the plasma nitrate response, but not the tumour necrosis response, to 5,6-MeXAA (30 mg/kg). It is suggested that serotonin is necessary for the induction of nitric oxide synthases and acts, either directly or indirectly, in concert with TNF. Serotonin agonists may have utility in increasing nitric oxide synthesis in response to TNF or to agents that induce TNF as part of their antitumour action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8269593     DOI: 10.1007/bf00686027

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Changes of oxygen tension in tumours induced by vasoconstrictor and vasodilator drugs.

Authors:  D B CATER; C M GRIGSON; D A WATKINSON
Journal:  Acta radiol       Date:  1962-12       Impact factor: 1.990

2.  Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours.

Authors:  G P Smith; S B Calveley; M J Smith; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1987-08

3.  Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

Authors:  L J Zwi; B C Baguley; J B Gavin; W R Wilson
Journal:  J Natl Cancer Inst       Date:  1989-07-05       Impact factor: 13.506

4.  Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.

Authors:  L L Thomsen; L M Ching; B C Baguley
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

5.  Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma).

Authors:  P M Mannucci; M Cattaneo; M T Canciani; M Maniezzo; M Vaglini; N Cascinelli
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

6.  The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse.

Authors:  Y Endo; M Nakamura
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis.

Authors:  E Veszelovszky; L L Thomsen; Z Li; B C Baguley
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.

Authors:  U Räth; M Kaufmann; H Schmid; J Hofmann; B Wiedenmann; A Kist; J Kempeni; E Schlick; G Bastert; B Kommerell
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice.

Authors:  M V Pimm; S J Gribben; T M Morris
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

Authors:  D J Chaplin
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

View more
  9 in total

1.  Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

Authors:  S Zhou; R Chin; P Kestell; M D Tingle; J W Paxton
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

Review 2.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

Review 3.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

4.  Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis.

Authors:  E Veszelovsky; N H Holford; L L Thomsen; R G Knowles; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Flavonoids: A versatile source of anticancer drugs.

Authors:  Maheep K Chahar; Neelu Sharma; Mahabeer P Dobhal; Yogesh C Joshi
Journal:  Pharmacogn Rev       Date:  2011-01

6.  Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice.

Authors:  Bruce C Baguley; Qi Ding; Emma Richardson
Journal:  Front Oncol       Date:  2014-11-05       Impact factor: 6.244

7.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

8.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

9.  The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.

Authors:  L Zhao; L-M Ching; P Kestell; B C Baguley
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.